Posts

Posted on

ZTE supports Ncell in completing preventive network maintenance at Everest Base Camp

PR Newswire

SHENZHEN, China, Nov. 29, 2020 /PRNewswire/ — ZTE Corporation (0763.HK / 000063.SZ), a major international provider of telecommunications, enterprise and consumer technology solutions for the Mobile Internet, today announced that it has supported Ncell successfully completing the preventive network maintenance at the southern slope of Everest Base Camp (EBC) at an altitude of 5,363 meters, further ensuring the network coverage quality of 2000-meter range around EBC.

The landmark base station of Ncell is the exclusive and highest base station on the southern slope of EBC. Since the commissioning in 2010, it has provided high-quality network services for local people and climbers.

For the network operation and maintenance (O&M), ZTE’s engineers have overcome various environmental difficulties, such as high altitude, storm wind and low temperature, and eventually completed the preventive network O&M, including power equipment replacement, wireless and transport network maintenance, and network quality optimization.

The landmark base station is mainly powered by solar energy and stand-by batteries. As it is located at a high altitude with severe environment, the maintenance of the base station is really difficult. In total, there are 10 base stations located in the Sagarmatha National Park area of Nepal, which are all constructed and maintained by ZTE. Since 2010, the base stations have continuously provided around-the-clock mobile network services for local residents and climbers.

Moving forward, Ncell will work with ZTE to achieve the mobile network coverage of the whole route of Mount Everest.

As a trusted and important partner of Ncell, ZTE has cooperated with Ncell for more than ten years to provide wireless, core network and transport network services in Nepal, meeting more than 60% of Ncell’s wireless network business needs. 

ZTE is a provider of advanced telecommunications systems, mobile devices and enterprise technology solutions to consumers, operators, companies and public sector customers. The company has been committed to providing customers with integrated end-to-end innovations to deliver excellence and value as the telecommunications and information technology sectors converge. Listed in the stock exchanges of Hong Kong and Shenzhen (H share stock code: 0763.HK / A share stock code: 000063.SZ), ZTE sells its products and services in more than 160 countries.

Media Contacts:

Margaret Ma                                                      
ZTE Corporation                                                
Tel: +86 755 26775189                                     
Email: [email protected]     

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/zte-supports-ncell-in-completing-preventive-network-maintenance-at-everest-base-camp-301181386.html

SOURCE ZTE Corporation

Posted on

Kaneka Develops Super Heat-Resistant Polyimide Film for 5G Millimeter Wave Zones

Kaneka Develops Super Heat-Resistant Polyimide Film for 5G Millimeter Wave Zones

－Expands lineup of 5G-supporting materials that are set to see sudden growth－

TOKYO–(BUSINESS WIRE)–
Kaneka Corporation (TOKYO: 4118) (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka) has developed “PixeoTM*1IB”, a super heat-resistant polyimide film for high-speed, high frequency 5G*2. The offering of samples began in October, and a full-scale rollout is scheduled for 2021. “PixeoTM IB” reduces the dielectric loss tangent*3 in high frequencies down to 0.0025, the global best level for polyimide film. This was achieved using the advanced polyimide development technologies that Kaneka has accumulated over many years. This makes possible the handling of 5G millimeter wave zones*4, which can realize high speed communications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201129005425/en/

“Pixeo™ IB”, a super heat-resistant polyimide film (Photo: Business Wire)

“Pixeo™ IB”, a super heat-resistant polyimide film (Photo: Business Wire)

With the emergence of 5G-equipped smartphones, which are said to reach communication speeds of around 100 times of 4G, 5G models in the global smartphone market are predicted to spread rapidly from here on. With both the millimeter wave-supporting “PixeoTM IB” and the “PixeoTM SR” that handles sub-6, Kaneka will expand their lineup of 5G-supporting products and grow sales of these materials that help digital devices reach more advanced functionalities.

In terms of materials for supporting high-speed information transmission, Kaneka owns a high share of the market with the super heat-resistant polyimide “PixeoTM”. However, Kaneka continues to provide a variety of solutions through different kinds of polyimide products. These include transparent polyimide film for flexible displays that acts as a glass substitute, polyimide varnish for a TFT*5 substrate, and ultrahigh thermal conductive graphite sheets.

*1. A super heat-resistant polyimide film with excellent processability achieved through applying thermoplastic polyimide layers on both surfaces of the core polyimide film. It’s used in two-layer flexible print circuit boards. Two-layer flexible print circuit boards can be made thinner than conventional three-layer boards, and also have superior reliability and dimensional stability.

*2. An abbreviation for the fifth generation mobile communication system (5th Generation).

*3. The amount of electrical energy lost within a material.

*4. A new frequency range that can be used with 5G. 5G can be split into the two frequency ranges of “sub-6” (3.6 GHz to 6 GHz) and “millimeter waves” (28 GHz to 300 GHz). It’s expected that in the future, usage of millimeter waves, which send communications faster through higher frequencies, will spread further.

*5. TFT is an abbreviation for a Thin Film Transistor. It controls light emission of organic EL elements.

KANEKA CORPORATION

Investor & Public Relations Department

Yuki Kakai

[email protected]

KEYWORDS: Japan Asia Pacific

INDUSTRY KEYWORDS: Chemicals/Plastics Technology Manufacturing Mobile/Wireless Networks Internet

MEDIA:

Photo
Photo
“Pixeo™ IB”, a super heat-resistant polyimide film (Photo: Business Wire)
Logo
Logo
Posted on

Telix Pharmaceuticals Limited Acquires TheraPharm GmbH, Broadening Reach to Hematologic Cancers and Transplant Medicine

MELBOURNE, Australia and BAAR, Switzerland, Nov. 29, 2020 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces it has entered into an agreement with Scintec Diagnostics GmbH (‘Scintec’) to acquire TheraPharm GmbH (‘TheraPharm’), a Swiss-German biotechnology company developing innovative diagnostic and therapeutic solutions in the field of hematology.

The acquisition of TheraPharm provides Telix with access to a portfolio of patents, technologies, production systems, clinical data and know-how in relation to the use of Molecularly Targeted Radiation (MTR) in hematology and immunology. TheraPharm is developing antibody MTR technology against CD66, a cell surface target highly expressed by neutrophils (a type of white blood cell) and tumor-infiltrating lymphocytes. As such, the technology has potentially very broad applications in the diagnosis and treatment of hematologic diseases (e.g. blood cancers), lymphoproliferative disorders and immune-mediated diseases (e.g. lupus, and multiple sclerosis). Of particular interest is the demonstrated use of the technology to safely and effectively perform bone marrow conditioning (BMC) prior to bone marrow stem cell transplant.

Telix CEO, Dr. Christian Behrenbruch stated, “Telix is committed to extending and improving the lives of patients with serious diseases. As such, the acquisition of TheraPharm and its MTR assets are uniquely aligned to Telix’s mission and technical strengths in antibody engineering and radiochemistry. TheraPharm’s technology has a significant role to play in BMC and stem cell transplantation across a broad range of blood cancers and rare diseases. The current approach to BMC employs highly toxic drugs that have a poor morbidity and mortality profile, and for which many patients are ineligible. MTR offers an excellent safety profile that may greatly expand the number of patients able to undergo life prolonging stem cell transplantation while greatly reducing the hospitalisation burden and cost associated with such procedures.”

TheraPharm co-founder and Managing Director, Dr. Klaus Bosslet added, “Over the past 5 years, TheraPharm, in collaboration with Dr. Kim Orchard from the University of Southampton (UK), has made excellent progress developing 90Y-besilesomab for the treatment of hematologic cancers and several related conditions including multiple myeloma, leukemia and amyloidosis. This unique asset is a logical addition to Telix’s portfolio, offering a potentially rapid development path to a first commercial indication for the treatment of patients with SALA, while at the same time having potentially broad applications for stem cell transplantation in patients with more common cancers of the blood, including multiple myeloma and leukemia. We look forward to joining the Telix team in order to expedite the development of products for this under-served field.”

Full transaction details, including financial terms, can be found via the Telix website and ASX portal here.

About
Hematopoietic
Stem Cell Transplant (HSCT)

Bone marrow conditioning (BMC) followed by hematopoietic stem cell transplantation (HSCT) is presently performed to treat patients with hematologic malignancies (blood cancers), with the objective of extending patient survival or achieving cure. HSCT is also performed for a broad range of non-cancer conditions. HSCT is preferentially performed in countries of high income (Europe >30,000, Americas >20,000, worldwide >65,000 p.a., respectively) and is growing at around 5% annually.

About
Systemic Amyloid Light-Chain Amyloidosis
(SALA)

SALA is a rare, but serious protein deposition disease, caused by a protein known as ‘amyloid’ that is produced by abnormal plasma cells residing in the bone marrow. As amyloid accumulates in the organs of the body, organ function will eventually deteriorate, ultimately causing organ failure. SALA has an estimated prevalence of 30,000 and 45,000 in United States and Europe, respectively and while a rare disease, SALA portends a very poor prognosis, with a median survival from diagnosis of ~11 months if untreated.

The current standard of care comprises of induction therapy (typically cyclophosphamide, bortezomib, dexamethasone) plus high dose melphalan BMC, followed by HSCT. This approach is typically only accessible to a small proportion of patients (<20%) who are able to tolerate induction therapy and melphalan BMC.

About Telix Pharmaceuticals
Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical needs in prostate, kidney and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.

About
TheraPharm
GmbH

TheraPharm is a biotechnology company specialised in the research, development and manufacturing of monoclonal antibodies for targeted radiation of hematopoietic malignant and non-malignant diseases, lymphoproliferative diseases, conditioning for allogeneic stem cells as well as in diagnostics of inflammatory diseases and bone marrow metastases.                

Telix Corporate Contact   Telix Investor Relations
Dr. Christian Behrenbruch Dr. David N. Cade
Telix Pharmaceuticals Limited Telix Pharmaceuticals Limited
CEO  CBO and Head of Investor Relations
Email: [email protected] Email: [email protected]



Posted on

Xuan Quynh LLC Joins PHILUX Global Funds to Participate in Luxembourg-based Infrastructure Fund for Vietnam and Laos

New York, Nov. 29, 2020 (GLOBE NEWSWIRE) — PHI Group, Inc. (www.phiglobal.com, PHIL), announced today that Xuan Quynh Limited Liability Company, a Vietnamese infrastructure construction and development company, has signed an agreement with PHI Luxembourg Development SA, the mother holding company for PHILUX Global Funds SCA, SICAV-RAIF, to join its “PHILUX Infrastructure Fund” compartment as a new partner in the first-ever Luxembourg-based infrastructure fund initiated for investment in Vietnam and Laos.

As one of the fastest growing economies in ASEAN, Vietnam is currently demanding for more foreign financial investment and technical assistance to narrow its infrastructure gap. According to the Global Infrastructure Outlook, Vietnam requires an investment of US$605 billion to meet 83 per cent of its infrastructure goals by 2040. Among the sectors that have been given utmost priorities are the urban transportation, road, rail and port infrastructure.

Currently, just 20 per cent of the country’s national roads are paved, and a recently approved plan to build Vietnam’s North-South high-speed railway, which allows passengers to travel between capital Hanoi and Ho Chi Minh City in about eight hours, will cost about 26 billion U.S. dollars.

The rising population in major cities in recent years has strained and exceeded capacity of the existing connectivity networks and utilities systems. With 50% of Vietnam’s population expected to be living in cities, Hanoi and Ho Chi Minh are building rapid transit systems exceeding US$22 billion in the hope of reducing private vehicle ownership and improving air quality.

Various expressway projects are planned and underway to improve connectivity within major cities. Similarly, development and upgrading of urban utilities infrastructure are announced and there are 44 planed PPP projects with total investment value worth up to US$ 120 billion in the road and power sectors.

Besides supporting infrastructure development for industrial zones, transportation, urban areas, seaports and airports in Vietnam, Xuan Quynh LLC intends to utilize the Luxembourg infrastructure fund for a number infrastructure projects in Laos as well.

Laos is one of the fastest growing economies in Southeast Asia region, with its average GDP growth rate for the last 20 years exceeding the level of 7 percent annually, one of the highest among ASEAN states. Nonetheless, inadequate infrastructure has been usually referred to as a major constraint to socio-economic development in Laos. Rapid economic growth has come with an increase in energy demand while power infrastructure in Laos is still under development. Telecommunication is another issues that needs to be addressed. But the most critical issue of Laos’ infrastructure is the road transportation system. As a completely landlocked country, road transport is the only means for improving socio-economic development through infrastructure. Unfortunately, road infrastructure in Laos is still limited, and according to the World Bank, only 56% of the rural population in Laos has access to all-season road. Thus, turning the country from a land-locked into a land-linked one is one of the most priorities of the Lao government, and this will see Laos as a connection hub among neighboring countries, bridging the more advanced economies of China, Thailand and Vietnam.

PHILUX Global Funds SCA, SICAV-RAIF (www.philux.eu), is a Luxembourg-based bank fund with multiple sub-fund compartments for investment in real estate, infrastructure, renewable energy and healthcare as well as the proposed Chu Lai Multiple Commodities Center (CMCC) and the Asia Diamond Exchange (ADE) in the Chu Lai Open Economic Zone, Quang Nam Province, Vietnam. This will be the first rough diamond exchange in Southeast Asia, comparable with diamond exchanges in Antwerp (https://www.awdc.be/) and Dubai (https://www.dmcc.ae/gateway-to-trade/commodities/diamonds).

Mr. Nguyen Canh Doat, Director of Xuan Quynh LLC, commented: “ We are very pleased to partner with PHILUX Infrastructure Fund to respond to the growing needs of infrastructure development in Vietnam and Laos and strongly believe that we will be able to achieve significant goals together through our cooperation.”

Henry Fahman, Chairman of PHILUX Global Funds SCA, SICAV-RAIF, stated: “We are delighted to work with Xuan Quynh to implement PHILUX Infrastructure Fund for Vietnam and Laos. By capitalizing on our combined experience and networks we will be well positioned to serve the needs of infrastructure development in Vietnam and Laos as well as create significant benefits for both companies, our shareholders and all other stakeholders involved.”

About PHILUX Global Funds and PHI Group, Inc.

PHILUX Global Funds SCA, SICAV-RAIF is a Luxembourg-based bank fund (www.philux.eu) with multiple sub-fund compartments for investment in real estate, infrastructure, renewable energy and healthcare as well as the proposed Chu Lai Multiple Commodities Center (CMCC) and the Asia Diamond Exchange (ADE) in the Chu Lai Open Economic Zone, Quang Nam Province, Vietnam.

PHI Group, Inc.(www.phiglobal.com), (PHIL), primarily focuses on mergers and acquisitions and invests in select industries and special situations that may substantially enhance shareholder value. In addition, the Company’s wholly-owned subsidiary, PHILUX Capital Advisors, Inc. (www.philuxcap.com) provides M&A consulting services and assists companies to go public and access international capital markets while also serving as the investment adviser to PHILUX Global Funds.

About Xuan Quynh LLC

Established in 1995, Xuan Quynh LLC is a multidisciplinary business operating mainly in the fields of construction – housing and resort real estate, road and bridge system, hydroelectricity, mining and a number of services including wholesale, retail, transport and accommodation.

With 25 years of establishment and development, Xuan Quynh LLC is operated by a team of experienced and dedicated managers and well-trained, professional and motivated staff with modern and advanced construction equipment and machinery. Xuan Quynh LLC has been the prestigious partner of several large-scale, high-quality construction projects in Vietnam.

Safe Harbor Act and Forward-looking Statements

This news release contains “forward-looking statements” pursuant to the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan” or “planned,” “will” or “should,” “expected,” “anticipates,” “draft,” “eventually” or “projected,” which are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements as a result of various factors.

Contact:

PHI Group, Inc.
+1-714-642-0571
[email protected]



Posted on

Sorrento to Participate in the 32nd Piper Sandler Healthcare Investor Conference

SAN DIEGO, Nov. 29, 2020 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”), is pleased to announce that Dr. Henry Ji, Chairman and CEO, will be participating in the Piper Sandler 32nd Annual Virtual Healthcare Conference.

A pre-recorded presentation is made available to participants and the public, in addition to 1 on 1 virtual meetings with selected investors taking place between 11/30/20 and 12/03/20.

Dr
.
Ji Pre-Recorded Investor Presentation can be accessed at the following Link: https://pipersandler.zoom.us/rec/play/7p6ebIhHbRkmmBaXffNQeGXSsRkhriEV56NBSFVTRQ9IBnxL6C4uvSfjlZXAayBAeewv7zWyCwLtr2XR.qMOgbDXGYEyaZYt2

(
Note:
L
ink expires 90 days after date of recording
)
.

For more information visit www.sorrentotherapeutics.com

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc. under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Certain statements contained in this presentation or in other documents of Sorrento Therapeutics, Inc. (the “Company” or “Sorrento”) and of any of its affiliates, along with certain statements that may be made by management of the Company orally in presenting this material, are or may be considered “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictly to historic or current facts. They use words such as “estimate,” “expect,” “intend,” “believe,” “plan,” “anticipate,” “potential,” “projected” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or condition. Sorrento cautions that these statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Statements regarding future action, future performance and/or future results including, without limitation, those relating to the timing for completion, and results of, scheduled or additional clinical trials and the FDA’s or other regulatory review and/or approval and commercial launch and sales results (if any) of the Company’s formulations and products and regulatory filings related to the same, and receipt by the Company of milestone and royalty payments may differ from those set forth in the forward-looking statements. Peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such sales levels will be achieved, if at all, or that such market size estimates will prove accurate.

The Company assumes no obligation to update forward-looking statements as circumstances change. Investors are advised to consult further disclosures that the Company makes or has made on related subjects in the Company’s most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings.

In presenting this material or responding to inquiries in connection with a presentation, management may refer to results, projections or performance measures that are not prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) as reported in the Company’s SEC filings. These results, projections or performance measures are non-GAAP measures and are not intended to replace or substitute for results measured under GAAP and are supplemental to GAAP reported results.

Because actual results are affected by these and other potential risks, contingencies and uncertainties, the Company cautions investors that actual results may differ materially from those expressed or implied in any forward-looking statement. It is not possible to predict or identify all such risks, contingencies and uncertainties. The Company identifies some of these factors in its SEC filings on Forms 10-K, 10-Q and 8-K, including Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are advised to consult the Company’s filings for a more complete listing of risk factors, contingencies and uncertainties affecting the Company and its business and financial performance.


Media and Investor Relations

Contact: Alexis Nahama, DVM (SVP Corporate Development)

Telephone: 1.858.203.4120

Email: [email protected]

ZTlido® and G-MAB™ are trademarks owned by Scilex Pharmaceuticals Inc. and Sorrento, respectively.

Seprehvir®, is a registered trademark of Virttu Biologics Limited, a wholly owned subsidiary of TNK Therapeutics, Inc. and part of the group of companies owned by Sorrento Therapeutics, Inc.

All other trademarks are the property of their respective owners.
© 2020 Sorrento Therapeutics, Inc. All Rights Reserved. 



Posted on

Ascentage Pharma Enters into an Agreement with University of Michigan to obtain an exclusive license for a MDM2 Degrader using PROTAC Technology

PR Newswire

SUZHOU, China and ROCKVILLE, Md., Nov. 29, 2020 /PRNewswire/ — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced it has entered into an agreement with the University of Michigan, through which the company may obtain the exclusive global rights to a MDM2 protein degrader developed using the Proteolysis-Targeting Chimeras (PROTACs) technology. The drug candidate is currently entering IND-enabling studies.

MDM2 is a key regulator of the tumor suppressor p53 and one of the most potent inhibitors of apoptosis discovered thus far. It has high expression in tumors and plays a key role in the occurrence and development of tumors. Binding to the MDM2 protein with high affinity, MDM2 inhibitor blocks the MDM2-p53 interactions and restore the tumor-suppressing activity of p53.1 Meanwhile, these MDM2 inhibitors present some challenges, including dose-limiting hematological toxicities, thus the urgent need to develop new generation of MDM2-targeting therapies in the treatment of cancer. The PROTAC technology has emerged as a new and promising approach that induces the degradation of targeted proteins through the ubiquitin-proteasome system (UPS), and it has received widespread interest from both the scientific community and industries since its introduction. Compared to conventional “occupancy-driven” pharmacological modality, the “event-driven” PROTAC technology has many advantages, such as high potency, high selectivity, with catalytic mode of action, and the ability to target undruggable proteins.2

Prof. Shaomeng Wang, Ph.D., C-Founder of Ascentage Pharma and Chairman of its Scientific Advisory Board, and Warner-Lambert/Parke-Davis Professor in Medicine, Professor of Internal Medicine, Pharmacology and Medicinal Chemistry, Director of Michigan Center for Therapeutic Innovation, University of Michigan, is a leading researcher in the field. Through structure-function studies of their previously discovered MDM2 inhibitors using the PROTAC technology, Dr. Wang’s research team has obtained potent and efficacious MDM2 degraders that could effectively induce rapid degradation of MDM2. The lead MDM2 degrader has achieved complete and durable tumor regression in a xenograft tumor model in mice3.

“As a new strategy to induce protein degradation, PROTAC has emerged as a novel modality in drug discovery,” said Dr. Wang. “Studies showed, PROTAC-induced MDM2 degradation can not only enhance the potency of MDM2 inhibitors, but also maintain a long-lasting suppression of MDM2 protein levels, providing a new strategy to the treatment of MDM2-driven tumors such as leukemia. We look forward to the further development of the asset by Ascentage Pharma.”

“The emergence of the PROTAC technology represents another breakthrough in the identification of small molecule drugs. The technology has received tremendous interest for its ability to target undruggable proteins,” said Dr. Dajun Yang, Chairman & CEO of Ascentage Pharma. “We are very pleased to reach this agreement with the University of Michigan, to begin the assessment of this PROTAC-based MDM2 degrader and potentially bring this important addition to our existing pipeline. Through the assessment and potential development of the MDM2 degrader, we hope soon that it will offer an effective therapy for serious unmet medical needs.”

References:

  1. Zhao, Y.; Aguilar, A.; Bernard, D.; Wang, S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 inhibitors) in clinical trials for cancer treatment. J. Med. Chem. 2015, 58, 1038−1052.
  2. Lai, A. C.; Crews, C. M. Induced protein degradation: an emerging drug discovery paradigm. Nat Rev. Drug Discov. 2017, 16, 101-114.
  3. Ryan P. Wurz and Victor J. Cee. Targeted Degradation of MDM2 as a New Approach to Improve the Efficacy of MDM2-p53 Inhibitors. J. Med. Chem. 2019, 62, 445−447.

About Ascentage Pharma

Ascentage Pharma (6855.HK) is a globally, clinical-stage biotechnology company engaged in developing novel therapies for cancers, CHB, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 6855.HK.

Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The company has built a pipeline of eight clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 Phase I/II clinical trials in the US, Australia, and China. HQP1351, the company’s core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia has been granted an Orphan Drug Designation (ODD) and a Fast Track designation by the US Food and Drug Administration (FDA), and a New Drug Application for the drug candidate has been submitted in China. To date, Ascentage Pharma has obtained a total of six ODDs from the FDA for four of the company’s investigational drug candidates.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/ascentage-pharma-enters-into-an-agreement-with-university-of-michigan-to-obtain-an-exclusive-license-for-a-mdm2-degrader-using-protac-technology-301181355.html

SOURCE Ascentage Pharma

Posted on

Gannex Appoints Former Takeda Head of Liver Disease Clinical Development Melissa Palmer, MD as Chief Medical Officer

PR Newswire


SHANGHAI
, Nov. 29, 2020 /PRNewswire/ — Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX:1672) and fully dedicated to the R&D and commercialization of new drugs in the field of NASH, announced today that Melissa Palmer, MD, an internationally renowned Hepatologist, will join the Company as Chief Medical Officer, effective December 1, 2020.

Prior to joining Gannex, Dr. Palmer was Head of Liver Disease Clinical Development at Takeda Pharmaceuticals. She has also held senior leadership positions at Shire Pharmaceuticals and Kadmon Corporation, where she was in charge of the global development of NASH and other liver disease programs. Prior to joining industry, she was clinical professor at NYU Langone Medical Center and director of Hepatology at NYU Plainview, NY. Since 1991, Dr. Palmer served as a Hepatology consultant to more than 40 biotech and pharmaceutical companies and was a primary investigator on numerous clinical trials in liver disease.

Dr. Palmer has authored over 100 publications, abstracts, articles, and book chapters, in addition to a best-selling book on liver disease “Dr. Melissa Palmer’s Guide to Hepatitis and Liver Disease”. She trained in Hepatology at Mount Sinai School of Medicine, where she also received her M.D. degree. She received her Bachelor of Science degree from Columbia University in New York City.

“As we continue to make breakthroughs in the clinical development of NASH, I am delighted to have Dr. Palmer join us at this pivotal time,” said Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis. “I am confident that Dr. Palmer’s exceptional skills and expertise will be a great asset as the Company advances its clinical development programs on a global basis.”

“I am excited about joining Gannex which has three clinical stage assets in NASH, ” said Dr. Palmer, “with impressive phase 2 data from the ASC40 trial in the US and recent US IND approval of ASC42, I am looking forward to working with the Company’s talented team and accelerating clinical development of these drug candidates for NASH patients globally.”

About Ascletis

Ascletis is an innovative R&D driven biotech and listed on Hong Kong Stock Exchange (1672.HK). Ascletis is committed to developing and commercializing innovative drugs in the areas of viral hepatitis, NASH and HIV/AIDS for unmet medical needs in China and globally. Led by a management team with deep expertise and a proven track record, Ascletis has developed into a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization.

Ascletis has three marketed products and thirteen R&D pipeline drug candidates or combination therapies (nine of them developed in-house). 1. Viral hepatitis: (i) Hepatitis B: focus on breakthrough therapies for HBV clinical cure with subcutaneously injected PD-L1 antibody – ASC22 and Pegasys® as cornerstone drugs. (ii) Hepatitis C: successfully launched all oral regimen of Asclevir® and Ganovo® combination (RDV/DNV regimen); and ASC18 fixed dose combination (FDC) is an upgraded version of RDV/DNV regimen with bridging study finished. 2. NASH: Gannex, a wholly-owned company of Ascletis, is fully dedicated to the R&D and commercialization of new drugs in the field of NASH. Gannex has three clinical stage drug candidates against three different targets – FASN, THR-beta and FXR, and three pre-clinical stage combination therapies. 3. HIV/AIDS: ASC09F is a FDC treatment of HIV targeting protease. The clinical trial application of ASC09F has been approved. For more information, please visit www.ascletis.com.

Cision View original content:http://www.prnewswire.com/news-releases/gannex-appoints-former-takeda-head-of-liver-disease-clinical-development-melissa-palmer-md-as-chief-medical-officer-301181353.html

SOURCE Ascletis Pharma Inc.

Posted on

New Comcast Report Finds Consumers Vastly Underestimate How Often Home Networks Are Targeted by Cyber Threats

New Comcast Report Finds Consumers Vastly Underestimate How Often Home Networks Are Targeted by Cyber Threats

Comcast Releases First Ever Xfinity Cyber Health Report, Outlining Key Observations on the State of Cybersecurity in Americans’ Connected Homes

Comcast has Protected Customers from Nearly 6 Billion Cybersecurity Threats Using xFi Advanced Security

PHILADELPHIA–(BUSINESS WIRE)–
Internet users in the United States vastly underestimate how often their home networks are targeted by cyber threats. That’s one of the key findings of the first ever Xfinity Cyber Health Report, which combines data from a new consumer survey with actual threat data collected by the xFi Advanced Security platform. As part of the report’s findings, Comcast announced that since January, xFi Advanced Security has blocked nearly six billion cybersecurity threats – representing an average of about 104 cybersecurity threats per home per month – protecting Xfinity Internet consumers from malicious threats targeting their home networks and the devices connected to them.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201129005027/en/

2020 Xfinity Cyber Health Report (Photo: Business Wire)

2020 Xfinity Cyber Health Report (Photo: Business Wire)

“The cyber threats facing even the most lightly connected homes have grown so numerous and so complex, that ordinary people can barely keep track, much less protect themselves,” said Noopur Davis, Chief Product and Information Security Officer, Comcast. “That’s why it’s essential that we provide people with smart, powerful tools, like xFi Advanced Security, that can spot and stop threats before they ever make it inside the home.”

Xfinity xFi users have on average 12 devices per home and added two devices over the past year, while high-end users have as many as 33 devices and added five since last year. And, 61 percent of consumers plan to buy at least one connected device during the upcoming holiday shopping season. With the number of connected devices in the home increasing, cybersecurity protection has never been more important.

The Xfinity Cyber Health Report summarizes the threats xFi Advanced Security has blocked for Xfinity Internet customers and the devices in their connected homes, providing an industry view into threats experienced by consumers. Key report findings include:

  • Consumers Underestimate Attack Volume: 95 percent of survey respondents underestimated the volume of attacks they face each month. The average volume indicated by respondents was 12 attacks per month. In reality, xFi Advanced Security blocks nine times that amount or an average of 104 security threats per month per household.
  • Mix of Devices Most Targeted: According to xFi Advanced Security data, the top five most vulnerable devices in connected homes are: 1) Computers & Laptops, 2) Smart Phones, 3) Networked Cameras, 4) Networked Storage Devices, 5) Streaming Video Devices.
  • Consumer Disconnect on Cybersafe Behavior: 96 percent of consumers surveyed were not familiar with how to answer six basic true/false cyberthreat questions. Further, a large majority (85 percent) of respondents indicated they are taking all the necessary security precautions needed to protect their home networks, and yet a clear majority (64 percent) admitted to behaviors like sharing passwords with friends and family that open themselves up to attack.
  • No Screen Means More Risk: What many people don’t realize is that connected devices can pose a security risk. Cyber criminals target them because many have little or no security protection and devices without screens can be more easily hacked without the consumer even knowing it. More than 4 in 5 consumers (83 percent) would not be 100 percent confident they’d know if one of their non-screen devices – such as a wireless printer or security camera – had been hacked.

In addition, the report includes a technology primer authored by the Chief Technology Officer at Comcast cybersecurity technology partner CUJO AI, about the rise of AI-based cyber threats; insight from Larry Maccherone, distinguished engineer and leader of DevSecOps at Comcast, on building security into products from the beginning, rather than “bolting on” after they launch; and five actionable tips from Patti Loyack, Vice President, xFi, Comcast, on how consumers can protect themselves.

Comcast’s xFi Advanced Security service was made free for all 20 million xFi customers across all of Comcast’s service areas in January. This product was developed based on customer feedback requesting a way to protect IoT devices in this connected home era. It uses AI and machine learning technology to monitor and analyze WiFi traffic in the home, and automatically blocks identified suspicious activity in real time. To activate this service, Xfinity xFi customers can log onto the Xfinity app and enable xFi Advanced Security.

About the Survey

The survey was conducted by Wakefield Research among 1,000 nationally representative U.S. adults ages 18 and older in September 2020, using an email invitation and an online survey. Results of any sample are subject to sampling variation. The magnitude of the variation is measurable and is affected by the number of interviews and the level of the percentages expressing the results. For the interviews conducted in this particular study, the chances are 95 in 100 that a survey result does not vary, plus or minus, by more than 3.1 percentage points from the result that would be obtained if interviews had been conducted with all persons in the universe represented by the sample.

About Comcast

Comcast Corporation (Nasdaq: CMCSA) is a global media and technology company with three primary businesses: Comcast Cable, NBCUniversal, and Sky. Comcast Cable is one of the United States’ largest high-speed internet, video, and phone providers to residential customers under the Xfinity brand, and also provides these services to businesses. It also provides wireless and security and automation services to residential customers under the Xfinity brand. NBCUniversal is global and operates news, entertainment and sports cable networks, the NBC and Telemundo broadcast networks, television production operations, television station groups, Universal Pictures, and Universal Parks and Resorts. Sky is one of Europe’s leading media and entertainment companies, connecting customers to a broad range of video content through its pay television services. It also provides communications services, including residential high-speed internet, phone, and wireless services. Sky operates the Sky News broadcast network and sports and entertainment networks, produces original content, and has exclusive content rights. Visit www.comcastcorporation.com for more information.

Joel Shadle

[email protected]

215-286-4675

Rachel Zabinski

[email protected]

215-286-1516

KEYWORDS: Pennsylvania United States North America

INDUSTRY KEYWORDS: Mobile/Wireless Technology Entertainment Security Other Technology Audio/Video Other Entertainment Networks TV and Radio Internet

MEDIA:

Logo
Logo
Photo
Photo
2020 Xfinity Cyber Health Report (Photo: Business Wire)
Posted on

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds K12 Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors With Losses in Excess of $100K to Contact Firm – LRN

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds K12 Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors With Losses in Excess of $100K to Contact Firm – LRN

NEW YORK–(BUSINESS WIRE)–
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of K12 Inc. (NYSE:LRN) between April 27, 2020 to September 18, 2020, inclusive (the “Class Period”) of the important January 19, 2021 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for K12 investors under the federal securities laws.

To join the K12 class action, go to http://www.rosenlegal.com/cases-register-1989.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

The Complaint alleges that K12 made false and misleading statements to the public throughout the Class Period and failed to disclose that: (1) K12 lacked the technological capabilities, infrastructure, and expertise to support the increased demand for virtual and blended education necessitated by the global pandemic; (2) K12 lacked adequate cyberattack protocols and protections to prevent the disabling of its computer systems; (3) K12 was unable to provide the necessary levels of administrative support and training to teachers, students, and parents; (4) and K12’s officers lacked a reasonable basis for their positive statements about the Company’s business, operations, and prospects. When the true details entered the market, the lawsuit claims that investors suffered damages.

On August 26, 2020, reports emerged that K12’s training for teachers in Miami-Dade County Public Schools, one of the largest school districts in the country, had been ineffective and unacceptable. On this news, K12’s shares fell by 7% over the course of two trading days, to close at $37.70 on August 27, 2020.

When classes in Miami-Dade started on August 31, 2020, K12’s platform experienced major technical issues, disruptions, and a series of cyberattacks. In response, the district’s superintendent revealed that the district had never executed its $15.3 million contract with K12. On this news, the price of K12 shares fell by 10.5% over the course of two trading days, to close at $34.89 on September 3, 2020.

A week later, facing overwhelming complaints from parents and teachers about K12’s platform and curriculum, the Miami-Dade County Public Schools Board voted to terminate their contract with K12. On this news, the price of K12 common shares once again fell drastically, by 11.5%, to close at $30.55 on September 10, 2020.

Other school districts also discovered K12’s inability to deliver on its promises. On September 17, 2020, following a loss of confidence in K12’s ability to provide educational solutions for the district, the Beaufort County School Board also voted to terminate its contract with K12. On this news, the price of K12’s shares fell 4.9%, to close at $27.21 on September 18, 2020.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 19, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1989.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

[email protected]

[email protected]

www.rosenlegal.com

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

EverQuote Mourns Sudden Passing of Co-Founder & CEO Seth Birnbaum

  • President Jayme
    Mendal
    Appointed
    CEO and Director 

CAMBRIDGE, Mass., Nov. 29, 2020 (GLOBE NEWSWIRE) — EverQuote, Inc. (Nasdaq: EVER), today issued the following statement: “It is with immeasurable sadness that we announce that Seth Birnbaum, Co-Founder and CEO, unexpectedly and peacefully passed away yesterday at his home. Seth was a sincere and deeply caring husband, father, friend and colleague. The entire EverQuote team mourns his tragic passing. On behalf of our Board of Directors, management team and employees, we extend our deepest sympathies to Seth’s family. Seth was a genuine, dynamic leader whose remarkable passion, vision and tenacity attracted the world-class team we have in place today, which serves as the foundation for EverQuote’s success. We will be forever grateful for his entrepreneurial spirit and the welcoming and caring environment he cultivated.“

The Board of Directors implemented the company’s succession plan and appointed Jayme Mendal, the company’s President, as its Chief Executive Officer and a member of the Board of Directors. Mr. Mendal joined EverQuote in 2017 and previously served as our Chief Operating Officer and before that as Chief Revenue Officer. David Blundin will continue to serve as Chairman of the Board of Directors.

Mr. Blundin issued the following statement on behalf of the Board: “We have experienced a great loss at EverQuote, and we are heartbroken by Seth’s passing. We are confident that Jayme and the rest of the EverQuote leadership team will continue to successfully drive forward in executing on the company’s mission. Seth was a visionary leader, thoughtful colleague and dear friend of many. We honor his numerous contributions and will miss him immensely.”

About EverQuote

EverQuote operates a leading online insurance marketplace, connecting consumers with insurance providers. The company’s mission is to empower insurance shoppers to better protect life’s most important assets—their family, property, and future. Our vision is to use data and technology to make insurance simpler, more affordable and personalized ultimately reducing cost and risk.

For more information, visit everquote.com and follow on Twitter @everquotelife, Instagram @everquotepics, and LinkedIn https://www.linkedin.com/company/everquote/.

Investor Relations Contact:

Brinlea Johnson
The Blueshirt Group
212-331-8424
[email protected]